View Filing Data

Print Document View Excel Document

DOCUMENT AND ENTITY INFORMATION	9 Months Ended
DOCUMENT AND ENTITY INFORMATION	Dec. 29, 2012 shares
Document And Entity Information [Abstract]
Entity Registrant Name	HAEMONETICS CORP
Entity Central Index Key	0000313143
Current Fiscal Year End Date	--03-30
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	Dec. 29, 2012
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	Q3
Amendment Flag	false
Entity Common Stock, Shares Outstanding	51,638,739

CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 29, 2012	Dec. 31, 2011	Dec. 29, 2012	Dec. 31, 2011
Net revenues	$ 247,395	$ 191,160	$ 642,048	$ 541,174
Cost of goods sold	134,280	95,229	337,058	266,545
Gross profit	113,115	95,931	304,990	274,629
Operating expenses:
Research and development	10,588	9,232	30,823	28,190
Selling, general and administrative	86,780	61,376	235,438	180,221
Contingent consideration income	0	0	0	(1,580)
Total operating expenses	97,368	70,608	266,261	206,831
Operating income	15,747	25,323	38,729	67,798
Other income (expense), net	(2,542)	140	(3,518)	370
Income before provision for income taxes	13,205	25,463	35,211	68,168
Provision for income taxes	3,301	7,211	8,972	19,088
Net income	$ 9,904	$ 18,252	$ 26,239	$ 49,080
Net income per share - basic (in dollars per share)	$ 0.19	$ 0.36	$ 0.51	$ 0.97
Net income per share - diluted (in dollars per share)	$ 0.19	$ 0.36	$ 0.50	$ 0.95
Weighted average shares outstanding
Basic (in shares)	51,707	50,154	51,364	50,818
Diluted (in shares)	52,606	50,876	52,264	51,666
Comprehensive income	$ 12,239	$ 18,585	$ 24,020	$ 48,657

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 29, 2012	Mar. 31, 2012
Current assets:
Cash and cash equivalents	$ 193,181	$ 228,861
Accounts receivable, less allowance of $1,715 at December 29, 2012 and $1,480 at March 31, 2012	167,347	135,464
Inventories, net	180,037	117,163
Deferred tax asset, net	10,807	9,665
Prepaid expenses and other current assets	47,510	35,976
Total current assets	598,882	527,129
Property, plant and equipment:
Land, building and building improvements	80,242	59,816
Plant equipment and machinery	196,869	136,057
Office equipment and information technology	100,955	88,185
Haemonetics equipment	241,435	226,476
Total property, plant and equipment	619,501	510,534
Less: accumulated depreciation	(356,373)	(348,877)
Net property, plant and equipment	263,128	161,657
Other assets:
Intangible assets, less amortization of $71,102 at December 29, 2012 and $54,973 at March 31, 2012	273,695	96,549
Goodwill	321,284	115,058
Deferred tax asset, long term	733	23
Other long-term assets	16,651	10,719
Total other assets	612,363	222,349
Total assets	1,474,373	911,135
Current liabilities:
Notes payable and current maturities of long-term debt	14,197	894
Accounts payable	53,077	35,425
Accrued payroll and related costs	40,897	29,451
Accrued income taxes	6,632	8,075
Deferred tax liability	250	64
Other liabilities	62,557	56,835
Total current liabilities	177,610	130,744
Long-term debt, net of current maturities	468,250	2,877
Long-term deferred tax liability	25,497	23,332
Other long-term liabilities	23,858	21,551
Stockholders’ equity:
Common stock, $0.01 par value; Authorized — 150,000,000 shares; Issued and outstanding —51,638,739 shares at December 29, 2012 and 50,603,798 shares at March 31, 2012	516	506
Additional paid-in capital	362,199	322,232
Retained earnings	409,553	400,783
Accumulated other comprehensive income	6,890	9,110
Total stockholders’ equity	779,158	732,631
Total liabilities and stockholders’ equity	$ 1,474,373	$ 911,135

CONSOLIDATED BALANCE SHEETS (Parentheticals) - USD ($) $ in Thousands	Dec. 29, 2012	Mar. 31, 2012
Accounts receivable, allowance	$ 1,715	$ 1,480
Intangible assets, amortization	$ 71,102	$ 54,973
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	150,000,000	150,000,000
Common stock, shares issued (in shares)	51,638,739	50,603,798
Common stock, shares outstanding (in shares)	51,638,739	50,603,798

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Dec. 29, 2012	Dec. 31, 2011
Cash Flows from Operating Activities:
Net income	$ 26,239	$ 49,080
Non cash items:
Depreciation and amortization	46,741	37,256
Stock compensation expense	7,931	6,727
Loss on sales of property, plant and equipment	472	280
Unrealized loss from hedging activities	617	1,365
Contingent consideration income	0	(1,580)
Reversal of interest expense on contingent consideration	0	(574)
Change in operating assets and liabilities:
Increase in accounts receivable, net	(32,165)	(1,461)
Increase in inventories	(12,732)	(23,047)
(Increase)/decrease in prepaid income taxes	(1,673)	14,949
Increase in other assets and other long-term liabilities	(4,489)	(874)
Tax benefit of exercise of stock options	3,905	1,410
Increase/(decrease) in accounts payable and accrued expenses	22,686	(2,188)
Net cash provided by operating activities	57,532	81,343
Cash Flows from Investing Activities:
Capital expenditures on property, plant and equipment	(49,685)	(36,959)
Proceeds from sale of property, plant and equipment	1,290	517
Acquisition of Whole Blood Business	(535,144)	0
Investment in Hemerus	(1,000)	0
Net cash used in investing activities	(584,539)	(36,442)
Cash Flows from Financing Activities:
Payments on long-term real estate mortgage	(658)	(882)
Net increase in short-term loans	4,557	1,529
Term Loan borrowings	475,000	0
Debt issuance costs	(5,461)	0
Proceeds from employee stock purchase plan	4,142	3,722
Proceeds from exercise of stock options	28,342	9,076
Excess tax benefit on exercise of stock options	3,158	839
Share repurchases	(18,042)	(49,998)
Net cash provided by (used in) financing activities	491,038	(35,714)
Effect of exchange rates on cash and cash equivalents	289	(522)
Net (Decrease)/Increase in Cash and Cash Equivalents	(35,680)	8,665
Cash and Cash Equivalents at Beginning of Year	228,861	196,707
Cash and Cash Equivalents at End of Period	193,181	205,372
Non-cash Investing and Financing Activities:
Transfers from inventory to fixed assets for placements of Haemonetics equipment	19,606	10,912
Supplemental Disclosures of Cash Flow Information:
Interest paid	4,020	322
Income taxes paid	$ 8,900	$ 6,098

BASIS OF PRESENTATION	9 Months Ended
BASIS OF PRESENTATION	Dec. 29, 2012
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	BASIS OF PRESENTATION Our accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles (“GAAP”) in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of our management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. All significant intercompany transactions have been eliminated. Operating results for the nine month period ended December 29, 2012 are not necessarily indicative of the results that may be expected for the full fiscal year ending March 30, 2013, or any other interim period. These unaudited consolidated financial statements should be read in conjunction with our audited consolidated financial statements and footnotes included in our annual report on Form 10-K for the fiscal year ended March 31, 2012. The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the financial statements to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated, and these financial statements reflect those material items that arose after the balance sheet date but prior to the issuance of the financial statements that would be considered recognized subsequent events. There were no material recognized subsequent events recorded in the December 29, 2012 consolidated financial statements. Our fiscal year ends on the Saturday closest to the last day of March. Fiscal years 2013 and 2012 include 52 weeks with each quarter having 13 weeks.

RECENT ACCOUNTING PRONOUNCEMENTS	9 Months Ended
RECENT ACCOUNTING PRONOUNCEMENTS	Dec. 29, 2012
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
RECENT ACCOUNTING PRONOUNCEMENTS	RECENT ACCOUNTING PRONOUNCEMENTS New pronouncements issued but not effective until after December 29, 2012 are not expected to have a material impact on financial position, results of operation or liquidity. Standards Implemented In June 2011, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2011-05, Comprehensive Income (Topic 220): Presentation of Comprehensive Income. Update No. 2011-05 updates the presentation requirements for comprehensive income to include total comprehensive income, the components of net income, and the components of other comprehensive income either in a single continuous statement of comprehensive income or in two separate but consecutive statements. The updated guidance does not affect how earnings per share is calculated or presented. The updated guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2011, and should be applied retrospectively. Early adoption is permitted and amendments do not require any transition disclosures. We adopted this standard in the first quarter of fiscal 2013 using the single continuous statement approach. Forthcoming Guidance In October 2012, the FASB issued ASU 2012-04, Technical Corrections and Improvements. The amendments in this update cover a wide range of Topics in the Accounting Standards Codification. These amendments include technical corrections and improvements to the Accounting Standards Codification and conforming amendments related to fair value measurements. The amendments in this update will be effective for fiscal periods beginning after December 15, 2012. The Company is currently evaluating the impact, if any, that the adoption of this pronouncement may have on its results of operations or financial position. In July 2012, the FASB issued ASU No. 2012-02, Intangibles-Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment. This standard, which amends the guidance on testing indefinite-lived intangible assets for impairment, other than goodwill, provides companies with the option to first perform a qualitative assessment before performing the two-step quantitative impairment test. If the company determines, on the basis of qualitative factors, that the fair value of the indefinite-lived intangible asset is more likely than not to exceed its carrying amount, then the company would not need to perform the two-step quantitative impairment test. This standard does not revise the requirement to test indefinite-lived intangible assets annually for impairment. This standard becomes effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012, with early adoption allowed. The Company does not expect the adoption of this standard will have a material effect on its financial condition or results of operations. In December 2011, the FASB issued ASU No. 2011-11 Balance Sheet: Disclosures about Offsetting Assets and Liabilities. This update requires an entity to disclose information about offsetting and related arrangements to enable users of its financial statements to understand the effect of those arrangements on its financial position. The objective of this disclosure is to facilitate comparison between those entities that prepare their financial statements on the basis of U.S. GAAP and those entities that prepare their financial statements on the basis of IFRS. The amended guidance is effective for annual reporting periods beginning on or after January 1, 2013, and interim periods within those annual periods. The Company is currently evaluating the impact, if any, that the adoption of this pronouncement may have on its results of operations or financial position.

ACQUISITIONS

9 Months Ended

Dec. 29, 2012

Business Combinations [Abstract]

ACQUISITIONS

Pall Acquisition

On August 1, 2012, we completed the acquisition from Pall Corporation (“Pall”) of substantially all of the assets relating to its blood collection, filtration, processing, storage, and re-infusion product lines, and all of the outstanding equity interest in Pall Mexico Manufacturing, S. de R.L. de C.V., a subsidiary of Pall based in Mexico pursuant to an Asset Purchase Agreement (the “Purchase Agreement”) with Pall. We refer to the acquired business as the “whole blood business.”

At the closing of the transaction, we paid Pall $535.1 million in cash consideration, which is subject to post-closing adjustments. During the three months ended December 29, 2012 we accrued $4.6 million for post-closing adjustments related to estimated historical earnings and working capital transferred which will be paid to Pall in the fourth quarter of fiscal 2013. We anticipate paying an additional $15.0 million upon replication and delivery of certain manufacturing assets of Pall's filter media business to Haemonetics by 2016. Until that time, Pall will manufacture and sell filter media to Haemonetics under a supply agreement.

We entered into a credit agreement on August 1, 2012 in connection with the transaction which includes a $475.0 million term loan to fund the majority of the cash paid to Pall. See Note 14 for a detailed description of the key terms and provisions of the credit agreement.

We acquired the whole blood business to provide access to the manual collection and whole blood markets and provide scope for introduction of automated solutions in those markets. The whole blood business manufactures and sells manual blood collection systems and filters and has operations in North America, Europe and Asia Pacific countries. Revenue from the sale of whole blood disposables will be reported within the blood center disposables product line.

The assets and liabilities acquired from Pall were recorded at fair value at the date of acquisition. During the current period, we updated the fair value of assets and liabilities recorded as of the date of acquisition with a corresponding adjustment to goodwill to reflect such updates to the allocation of purchase price.

The allocation of purchase price, and assessment of useful lives, is preliminary and based on management's judgments after evaluating several factors, including preliminary valuation assessments of tangible and intangible assets and preliminary estimates of the fair value of liabilities assumed. The allocation of the purchase price to the assets acquired and liabilities assumed will be completed when the working capital adjustment is finalized and valuation assessments of inventory, property, plant and equipment and intangible assets, and estimates of the fair value of liabilities assumed are completed. We expect to complete these valuations by March 30, 2013.

The preliminary allocation of the purchase price to the estimated fair value of the acquired assets and liabilities is summarized as follows:



Asset class	Amounts Recognized as of December 29, 2012 (Provisional)
(in thousands)
Inventories	$	50,741
Property, plant and equipment	93,847
Intangible assets	188,500
Other assets/liabilities, net	320
Goodwill	206,303
Fair value of net assets acquired	$	539,711

The adjusted fair value of the acquired assets and liabilities are reflected in the Consolidated Balance Sheets.

The provisional allocation of purchase price changed as compared to the initial allocation as of September 29, 2012 as follows: inventory reduced by $1.7 million, property, plant and equipment increased by $23.1 million, intangible assets reduced by $18.3 million, other assets increased by $0.1 million, liabilities reduced by $2.0 million and goodwill decreased by $0.7 million. This is represented by an increase in purchase consideration of $4.5 million arising from provisional customary adjustments.

The $188.5 million of acquired intangible assets was allocated to acquired technology and customer relationships at preliminary fair values of $61.0 million and $127.5 million, respectively. The acquired assets are amortized over the preliminary estimate of their useful lives of 11 years on a straight-line basis. We will conclude on the useful lives of acquired assets in connection with finalizing the overall purchase price allocation. We recorded $3.7 million and $7.1 million in amortization expense relating to the acquired intangible assets for the three and nine months ended December 29, 2012.

Preliminary goodwill represents the excess of the purchase price over the fair value of the net assets. Preliminary goodwill of $206.3 million represents future economic benefits expected to arise from work force at the various plants and locations and significant technological know-how in filter manufacturing. All of the domestic goodwill is deductible for tax purposes.

Revenue and earnings for the whole blood business from acquisition was $83.5 million and $8.0 million, respectively. The estimated impact to earnings includes $11.1 million of costs of goods sold related to the increase in fair value of acquired inventory.

We recognized $3.2 million of transaction costs related to the whole blood acquisition in the consolidated statements of income and comprehensive income for the nine months ended December 29, 2012.

The following represents the pro forma consolidated statements of income and comprehensive income as if the acquisition of the whole blood business had been included in our consolidated results on April 3, 2011. The common stock weighted average number of shares used in calculating the pro-forma earnings per share has been retroactively adjusted for the stock split:



	Nine Months Ended
(in thousands)	December 29, 2012		December 31, 2011
Net sales	$	713,981	$	703,023
Net income	42,975		47,961
Basic earnings per share	$	0.84	$	0.94
Diluted earnings per share	$	0.82	$	0.93

The unaudited consolidated pro-forma financial information above includes the following significant adjustments made to account for certain costs which would have been incurred if the acquisition had been completed on April 3, 2011, as adjusted for the applicable tax impact. As our acquisition of the whole blood business was completed on August 1, 2012, the pro-forma adjustments for the nine months ended December 29, 2012 in the table below only include the required adjustments through August 1, 2012.



	Nine Months Ended
(in thousands)	December 29, 2012			December 31, 2011
Transaction costs (1)	$	3,184		$	—
Amortization of inventory fair value adjustment (2)	11,067			(11,067		)
Amortization of acquired intangible assets (3)	(5,712		)	(12,852		)
Interest expense incurred on acquisition financing (4)	(3,173		)	(7,137		)
Selling, general and admin expenses (5)	(3,513		)	(7,905		)


(1)	Eliminated transactions costs as these non-recurring costs were incurred in the first and second quarters of FY13.

(2)

Added additional expense in the period ended December 31, 2011 to reflect the inventory fair value adjustments which would have been amortized had the transaction been consummated on April 3, 2011 as the corresponding inventory would have been completely sold during the first two quarters of 2011. Also, deducted the actual inventory fair value adjustment recorded in the nine months ended December 29, 2012 to reflect the pro-forma consumption of inventory in 2011.


(3)	Added additional amortization of the acquired whole blood intangible assets recognized at fair value in purchase accounting.


(4)	Added additional interest expense for the debt used to finance the acquisition.

(5)

Additional investments in infrastructure costs to replicate certain support functions performed by division or corporate organizations of Pall that did not transfer in the acquisition. These costs are primarily related to information technology infrastructure and application costs, and personnel costs required to expand regional and corporate administrative and sales support functions. These costs are not intended to be representative of actual costs incurred by Pall Corporation, and represent Haemonetics' best estimate of future incremental costs on an annualized basis. Actual incremental investments may differ from these estimates.

Prior to the acquisition, we had purchased filters from the whole blood business for inclusion in some of our devices. The transactional value between both parties approximated $10.0 million which was recorded as a cost of sale. At the acquisition date, there were no amounts due to or due from the whole blood business.

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1500-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1524-128463

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e7000-128479

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4922-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4934-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4926-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e6996-128479

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1383-128463

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 88-16
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph F4
-Subparagraph e
-Appendix F

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 51, 52
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 67-73
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

EARNINGS PER SHARE ("EPS")

9 Months Ended

Dec. 29, 2012

Earnings Per Share [Abstract]

EARNINGS PER SHARE (EPS)

EARNINGS PER SHARE (“EPS”)

The following table provides a reconciliation of the numerators and denominators of the basic and diluted earnings per share computations. Basic EPS is computed by dividing net income by weighted average shares outstanding. Diluted EPS includes the effect of potentially dilutive common shares. The common stock weighted average number of shares has been retroactively adjusted for the stock split.



	Three Months Ended
	December 29, 2012		December 31, 2011
	(in thousands, except per share amounts)
Basic EPS
Net income	$	9,904	$	18,252
Weighted average shares	51,707		50,154
Basic income per share	$	0.19	$	0.36
Diluted EPS
Net income	$	9,904	$	18,252
Basic weighted average shares	51,707		50,154
Net effect of common stock equivalents	899		722
Diluted weighted average shares	52,606		50,876
Diluted income per share	$	0.19	$	0.36



	Nine Months Ended
	December 29, 2012		December 31, 2011
	(in thousands, except per share amounts)
Basic EPS
Net income	$	26,239	$	49,080
Weighted average shares	51,364		50,818
Basic income per share	$	0.51	$	0.97
Diluted EPS
Net income	$	26,239	$	49,080
Basic weighted average shares	51,364		50,818
Net effect of common stock equivalents	900		848
Diluted weighted average shares	52,264		51,666
Diluted income per share	$	0.50	$	0.95

Weighted average shares outstanding, assuming dilution, excludes the impact of 0.7 million and 0.4 million stock options for the three and nine months ended December 29, 2012, respectively, and 1.8 million and 1.2 million stock options for the three and nine months ended December 31, 2011, respectively, because these securities were anti-dilutive during the noted periods.

STOCK-BASED COMPENSATION

9 Months Ended

Dec. 29, 2012

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

STOCK-BASED COMPENSATION

Stock-based compensation expense of $7.9 million and $6.7 million was recognized for the nine months ended December 29, 2012 and December 31, 2011, respectively. The related income tax benefit recognized was $2.5 million and $2.0 million for the nine months ended December 29, 2012 and December 31, 2011, respectively.

The weighted average fair value for our options granted was $9.76 and $8.15 for the nine months ended December 29, 2012 and December 31, 2011, respectively. The assumptions utilized for estimating the fair value of option grants during the periods presented are as follows:



	Nine Months Ended
	December 29, 2012		December 31, 2011
Stock Options Black-Scholes assumptions (weighted average):
Volatility	26.94	%	27.95	%
Expected life (years)	5.0		4.9
Risk-free interest rate	0.72	%	1.12	%
Dividend yield	—	%	—	%

During the nine months ended December 29, 2012 and December 31, 2011, there were 150,763 and 154,520 shares, respectively, purchased under the Employee Stock Purchase Plan at an average price of $27.47 and $24.58 per share, respectively.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 50
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 40
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 14

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph 64, 65, A240
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Statement of Position (SOP)
-Number 93-6
-Paragraph 53
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

PRODUCT WARRANTIES

9 Months Ended

Dec. 29, 2012

Product Warranties [Abstract]

PRODUCT WARRANTIES

We generally provide a warranty on parts and labor for one year after the sale and installation of each device. We also warrant our disposables products through their use or expiration. We estimate our potential warranty expense based on our historical warranty experience, and we periodically assess the adequacy of our warranty accrual and make adjustments as necessary.



	Nine Months Ended
(in thousands)	December 29, 2012			December 31, 2011
Warranty accrual as of the beginning of the period	$	796		$	1,273
Warranty provision	884			1,897
Warranty spending	(1,076		)	(1,680		)
Warranty accrual as of the end of the period	$	604		$	1,490

INVENTORIES

9 Months Ended

Dec. 29, 2012

Inventory Disclosure [Abstract]

INVENTORIES

Inventories are stated at the lower of cost or market and include the cost of material, labor and manufacturing overhead. Cost is determined on the first-in, first-out method.



(in thousands)	December 29, 2012		March 31, 2012
Raw materials	$	58,508	$	41,219
Work-in-process	8,979		4,640
Finished goods	112,550		71,304
	$	180,037	$	117,163

DERIVATIVES AND FAIR VALUE MEASUREMENTS

9 Months Ended

Dec. 29, 2012

Derivatives and Fair Value Measurements [Abstract]

DERIVATIVES AND FAIR VALUE MEASUREMENTS

We manufacture, market and sell our products globally. For the nine months ended December 29, 2012, approximately 49.4% of our sales were generated outside the U.S. generally in local currencies. We also incur certain manufacturing, marketing and selling costs in international markets in local currency.

Accordingly, our earnings and cash flows are exposed to market risk from changes in foreign currency exchange rates relative to the U.S. Dollar, our reporting currency. We have a program in place that is designed to mitigate our exposure to changes in foreign currency exchange rates. That program includes the use of derivative financial instruments to minimize for a period of time, the unforeseen impact on our financial results from changes in foreign exchange rates. We utilize foreign currency forward contracts to hedge the anticipated cash flows from transactions denominated in foreign currencies, primarily the Japanese Yen and the Euro, and to a lesser extent the Swiss Franc, British Pound Sterling and the Canadian Dollar. This does not eliminate the volatility of foreign exchange rates, but because we generally enter into forward contracts one year out, rates are fixed for a one-year period, thereby facilitating financial planning and resource allocation.

Designated Foreign Currency Hedge Contracts

All of our designated foreign currency hedge contracts as of December 29, 2012 and March 31, 2012 were cash flow hedges under ASC Topic 815, Derivatives and Hedging. We record the effective portion of any change in the fair value of designated foreign currency hedge contracts in Other Comprehensive Income in the Statement of Stockholders' Equity until the related third-party transaction occurs. Once the related third-party transaction occurs, we reclassify the effective portion of any related gain or loss on the designated foreign currency hedge contracts to earnings. In the event the hedged forecasted transaction does not occur, or it becomes probable that it will not occur, we would reclassify the amount of any gain or loss on the related cash flow hedge to earnings at that time. We had designated foreign currency hedge contracts outstanding in the contract amount of $133.4 million as of December 29, 2012 and $162.1 million as of March 31, 2012.

During the nine months ended December 29, 2012, we recognized net gains of $2.0 million in earnings on our cash flow hedges. For the nine months ended December 29, 2012, a $0.4 million gain related to foreign exchange hedge contracts, net of tax, was recorded in Accumulated Other Comprehensive Income to recognize the effective portion of the fair value of any designated foreign currency hedge contracts that are, or previously were, designated as foreign currency cash flow hedges, as compared to net losses of $0.4 million for the nine months ended December 31, 2011. At December 29, 2012, losses of $0.4 million, net of tax, may be reclassified to earnings within the next twelve months. All currency cash flow hedges outstanding as of December 29, 2012 mature within twelve months.

Non-designated Foreign Currency Contracts

We manage our exposure to changes in foreign currency on a consolidated basis to take advantage of offsetting transactions and balances. We use foreign currency forward contracts as a part of our strategy to manage exposure related to foreign currency denominated monetary assets and liabilities. These foreign currency forward contracts are entered into for periods consistent with currency transaction exposures, generally one month. They are not designated as cash flow or fair value hedges under ASC Topic 815. These forward contracts are marked-to-market with changes in fair value recorded to earnings. We had non-designated foreign currency hedge contracts under ASC Topic 815 outstanding in the contract amount of $68.9 million as of December 29, 2012 and $45.5 million as of March 31, 2012.

Interest Rate Swaps

On August 1, 2012, we entered into a credit agreement which provided for a $475.0 million term loan (“Term Loan”). Under the terms of this Credit Agreement, the Company may borrow at a spread to an index, including the LIBOR index of 1-month, 3-months, 6-months, etc. From the date of the Credit Agreement, the Company has chosen to borrow against the 1-month USD-LIBOR-BBA rounded up, if necessary, to the nearest 1/16^th of 1% (“Adjusted LIBOR”). The terms of the Credit Agreement also allow us to borrow in multiple tranches. While we currently borrow in a single tranche, in the future, we may choose to borrow in multiple tranches.

Accordingly, our earnings and cash flows are exposed to interest rate risk from changes in adjusted LIBOR. Part of our interest rate risk management strategy includes the use of interest rate swaps to mitigate our exposure to changes in variable interest rates. Our objective in using interest rate swaps is to add stability to interest expense and to manage and reduce the risk inherent in interest rate fluctuations. If the interest rate swap qualifies for hedge accounting, we formally document our hedge relationships (including identifying the hedged instrument and hedged item) at hedge inception. On a quarterly basis, we assess whether the interest rate swaps are highly effective in offsetting changes in the cash flow of the hedged item. We do not hold or issue interest rate swaps for trading purposes. We manage the credit risk of the counterparties by dealing only with institutions that we consider financially sound and consider the risk of non-performance to be remote.

On December 21, 2012, we entered into two interest rate swap agreements ("the swaps"), whereby we receive Adjusted LIBOR and pay an average fixed rate of 0.68% on a total notional value of $250.0 million of debt. The interest rate swaps mature on August 1, 2017. The Company designated the interest rate swaps as a cash flow hedge of variable interest rate risk associated with $250.0 million of indebtedness. For the nine months ended December 29, 2012, $0.6 million of losses, net of tax, were recorded in Accumulated Other Comprehensive Income to recognize the effective portion of the fair value of interest rate swaps that qualify as cash flow hedges. At December 29, 2012, losses of $0.1 million may be reclassified to earnings within the next twelve months.

We did not have fair value hedges or net investment hedges outstanding as of December 29, 2012 or March 31, 2012.

Fair Value of Derivative Instruments

The following table presents the effect of our derivative instruments designated as cash flow hedges and those not designated as hedging instruments under ASC Topic 815 in our consolidated statements of income and consolidated income for the nine months ended December 29, 2012.



Derivative Instruments	Amount of Loss Recognized in AOCI (Effective Portion)			Amount of Loss Reclassified from AOCI into Earnings (Effective Portion)		Location in Statement of Operations	Amount of loss Excluded from Effectiveness Testing (*)			Location in Statement of Operations
(in thousands)
Designated foreign currency hedge contracts, net of tax	$	(374	)	$	2,011	Net revenues, COGS, and SG&A	$	(380	)	Other income (expense), net
Non-designated foreign currency hedge contracts	—			—			(930		)	Other income (expense)
Designated interest rate swaps, net of tax	576			$	—	Interest income (expense), net	$	—

(*) We exclude the difference between the spot rate and hedge forward rate from our effectiveness testing.

ASC Topic 815 requires all derivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. We determine the fair value of our derivative instruments using the framework prescribed by ASC Topic 820, Fair Value Measurements and Disclosures, by considering the estimated amount we would receive or pay to sell or transfer these instruments at the reporting date and by taking into account current interest rates, currency exchange rates, current interest rate curves, interest rate volatilities, the creditworthiness of the counterparty for assets, and our creditworthiness for liabilities. In certain instances, we may utilize financial models to measure fair value. Generally, we use inputs that include quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; other observable inputs for the asset or liability; and inputs derived principally from, or corroborated by, observable market data by correlation or other means. As of December 29, 2012, we have classified our derivative assets and liabilities within Level 2 of the fair value hierarchy prescribed by ASC Topic 815, as discussed below, because these observable inputs are available for substantially the full term of our derivative instruments.

The following tables present the fair value of our derivative instruments as they appear in our consolidated balance sheets as of December 29, 2012 by type of contract and whether it is a qualifying hedge under ASC Topic 815.



(in thousands)	Location in Balance Sheet	As of December 29, 2012		As of March 31, 2012
Derivative Assets:
Designated foreign currency hedge contracts	Other current assets	$	3,904	$	6,186
		$	3,904	$	6,186
Derivative Liabilities:
Designated foreign currency hedge contracts	Other current liabilities	$	1,343	$	1,185
Designated interest rate swaps	Other current liabilities	$	927	$	—
		$	2,270	$	1,185

Other Fair Value Measurements

ASC Topic 820, Fair Value Measurements and Disclosures, defines fair value, establishes a framework for measuring fair value in accordance with U.S. GAAP, and expands disclosures about fair value measurements. ASC Topic 820 does not require any new fair value measurements; rather, it applies to other accounting pronouncements that require or permit fair value measurements. In accordance with ASC Topic 820, for the three and nine months ended December 29, 2012, we applied the requirements under ASC Topic 820 to our non-financial assets and non-financial liabilities. As we did not have an impairment of any non-financial assets or non-financial liabilities, there was no disclosure required relating to our non-financial assets or non-financial liabilities.

On a recurring basis, we measure certain financial assets and financial liabilities at fair value, including our money market funds, foreign currency hedge contracts, and contingent consideration. ASC Topic 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. We base fair value upon quoted market prices, where available. Where quoted market prices or other observable inputs are not available, we apply valuation techniques to estimate fair value.

ASC Topic 820 establishes a three-level valuation hierarchy for disclosure of fair value measurements. The categorization of assets and liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows:


•	Level 1 — Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.


•	Level 2 — Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.


•	Level 3 — Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.

Our money market funds carried at fair value are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices.

We recognize all derivative financial instruments in our consolidated financial statements at fair value in accordance with ASC Topic 815, Derivatives and Hedging. We determine the fair value of these instruments using the framework prescribed by ASC Topic 820 by considering the estimated amount we would receive or pay to terminate these agreements at the reporting date and by taking into account current spot rates, current interest rates, current interest rate curves, interest rate volatilities, the creditworthiness of the counterparty for assets, and our creditworthiness for liabilities. We have classified our foreign currency hedge contracts and interest rate swaps within Level 2 of the fair value hierarchy because these observable inputs are available for substantially the full term of our derivative instruments. The fair value of our foreign currency hedge contracts is the estimated amount that the Company would receive or pay upon liquidation of the contracts, taking into account the change in currency exchange rates. The fair value of our interest rate swaps is determined using widely accepted valuation techniques, using observable market-based inputs, including interest rate curves and interest rate volatility and reflects the contractual terms of these instruments, including the period to maturity.

Fair Value Measured on a Recurring Basis

Financial assets and financial liabilities measured at fair value on a recurring basis consist of the following as of December 29, 2012:



(in thousands)	Quoted Market Prices for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
Assets
Money market funds	$	142,919	$	—	$	—	$	142,919
Foreign currency hedge contracts	—		$	3,904	—		3,904
	$	142,919	$	3,904	$	—	$	146,823
Liabilities
Foreign currency hedge contracts	$	—	$	1,343	$	—	$	1,343
Interest rate swap	—		927		—		927
	$	—	$	2,270	$	—	$	2,270

Release of Neoteric Contingent Consideration

Under ASC Topic 805, Business Combinations, we established a liability for payments to former shareholders of Neoteric which were contingent on the performance of the Blood Track business in the first three years post-acquisition, beginning with fiscal 2010. We have reviewed the expected performance versus the performance thresholds for payment. Because the expected performance thresholds will not be achieved, we recorded an adjustment to the fair value of the contingent consideration liability. This appears as contingent consideration income of $1.6 million in the accompanying consolidated statements of income and comprehensive income for the nine months ended December 31, 2011.

In September 2011, we entered into an agreement to release the Company from the contingent consideration due to the former shareholders of Neoteric. Under the terms of the agreement, the former shareholders of Neoteric received $0.7 million in exchange for releasing the Company from any future claims for contingent consideration. The Company paid the $0.7 million settlement amount during September 2011 and has recorded the associated expense in the selling, general and administrative line item in the accompanying consolidated statements of income and comprehensive income.

Other Fair Value Disclosures

The fair value of our real estate mortgage obligation was $2.3 million and $3.1 million at December 29, 2012 and March 31, 2012, respectively. This liability is a Level 2 financial instrument and the fair value has been determined using a net present value calculation of the future mortgage payments due, discounted by a rate derived from corresponding U.S. Treasury rates. The $475.0 million term loan is carried at amortized cost and accounts receivable and accounts payable are also reported at their cost which approximates fair value.

INCOME TAXES	9 Months Ended
INCOME TAXES	Dec. 29, 2012
Income Tax Disclosure [Abstract]
Income Taxes	INCOME TAXES The reported tax rate was 25.0% and 25.5% for the three and nine months ended December 29, 2012, respectively. Our reported tax rate is lower than the federal statutory tax rate in both periods reported primarily due to lower foreign tax rates, including tax benefits associated with our operations in Switzerland. We conduct business globally and, as a result, file consolidated federal, consolidated and separate state and foreign income tax returns in multiple jurisdictions. In the normal course of business, we are subject to examination by taxing authorities throughout the world in jurisdictions including the U.S., Japan, Germany, France, the United Kingdom, and Switzerland. With few exceptions, we are no longer subject to U.S. federal, state and local, or foreign income tax examinations for years before 2007.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 136, 172
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph h
-Article 4

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 43, 44, 45, 46, 47, 48, 49
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

COMMITMENTS AND CONTINGENCIES	9 Months Ended
COMMITMENTS AND CONTINGENCIES	Dec. 29, 2012
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES We are presently engaged in various legal actions, and although ultimate liability cannot be determined at the present time, we believe, based on consultation with counsel, that any such liability will not materially affect our consolidated financial position or our results of operations. During the third quarter of fiscal 2013, we issued a field action letter to blood center customers requesting visual inspection of a component of certain whole blood collection sets, due to the potential for a leak to occur at a very low frequency. The component, referred to as a Y connector, was supplied by a contract manufacturer. We recorded inventory reserves of $6.1 million in cost of goods sold within the consolidated statement of income for the three months ended December 29, 2012 for removal of affected whole blood collection sets from inventory for destruction or rework. We will pursue all available means of financial recovery related to this inventory loss. However, no salvage or recovery value from these efforts was recorded as we cannot currently conclude whether a favorable outcome will result. During the first quarter of fiscal 2012, we received customer complaints in Europe regarding a quality issue with our High Separation Core Bowl (“HS Core”), a plasma disposable product used primarily to collect plasma for transfusion. Certain of these customers also made subsequent claims regarding financial losses alleged to have been incurred as a result of this matter. Certain of these claims were recoverable under our product liability insurance policy. To date, we have recognized a $10.3 million liability offset by insurance receivables of $8.2 million and an expense of $2.1 million. As of December 29, 2012, all liabilities incurred as a result of the HS Core issue have been paid and receivables from our insurers have been collected. We do not expect to record additional material claims or insurance recoveries related to this matter.

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14435-108349

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 14
-Paragraph 3
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 9, 10, 11, 12
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

SEGMENT INFORMATION

9 Months Ended

Dec. 29, 2012

Segment Reporting [Abstract]

SEGMENT INFORMATION

Segment Definition Criteria

We manage our business on the basis of one operating segment: the design, manufacture, and marketing of blood management solutions. Our chief operating decision-maker uses consolidated results to make operating and strategic decisions. Manufacturing processes, as well as the regulatory environment in which we operate, are largely the same for all product lines.

Enterprise-Wide Disclosures about Product and Services

We have four global product families: plasma, blood center, hospital, and software solutions. Beginning August 1, 2012, we integrated the whole blood business as part of the blood center product family.

Our products include manual blood collection kits, devices and the disposable single-use sterile kits used with these devices. Disposables include the plasma, blood center, and hospital product families. Plasma consists of the disposables used to perform apheresis for the separation of whole blood components and subsequent collection of plasma to be used as a raw material for biologically derived pharmaceuticals (also known as source plasma). Blood center consists of manual collection kits and disposables which separate whole blood for the subsequent collection of platelets, plasma, red cells, or a combination of these components for transfusion to patients. Hospital consists of surgical disposables (principally the Cell Saver^® and Cell Saver Elite ^® autologous blood recovery systems targeted toward procedures that involve rapid, high volume blood loss such as cardiovascular surgeries and the cardioPAT^® cardiovascular perioperative autotransfusion system designed to remain with the patient following cardiovascular surgery to recover blood and the patient’s red cells to prepare them for reinfusion), the OrthoPAT^® orthopedic perioperative autotransfusion system designed to operate both during and after orthopedic surgery to recover and wash the patient’s red cells to prepare them for reinfusion, and diagnostics products (principally the TEG^® Thrombelastograph^® hemostasis analyzer used to help assess a surgical patient’s blood clotting ability before, during and after surgery). Software solutions include information technology platforms that assist blood centers, plasma centers, and hospitals to more effectively manage regulatory compliance and operational efficiency.

Revenues from External Customers:



	Three Months Ended
(in thousands)	December 29, 2012		December 31, 2011
Disposable revenues
Plasma disposables	$	68,102	$	69,040
Blood center disposables
Platelet	45,139		44,383
Red cell	11,752		12,162
Whole blood	54,894		—
	111,785		56,545
Hospital disposables
Surgical	18,900		17,333
OrthoPAT	7,090		7,755
Diagnostics	6,761		5,681
	32,751		30,769
Disposables revenue	212,638		156,354
Software solutions	16,008		15,849
Equipment & other	18,749		18,957
Net revenues	$	247,395	$	191,160



	Nine Months Ended
(in thousands)	December 29, 2012		December 31, 2011
Disposable revenues
Plasma disposables	$	200,657	$	196,206
Blood center disposables
Platelet	125,579		123,888
Red cell	35,738		35,676
Whole blood	83,514		—
	244,831		159,564
Hospital disposables
Surgical	55,965		49,281
OrthoPAT	22,276		22,804
Diagnostics	20,196		16,955
	98,437		89,040
Disposables revenue	543,925		444,810
Software solutions	51,354		51,208
Equipment & other	46,769		45,156
Net revenues	$	642,048	$	541,174

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 131
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

RESTRUCTURING

9 Months Ended

Dec. 29, 2012

Restructuring and Related Activities [Abstract]

REORGANIZATION

RESTRUCTURING

During the nine months ended December 29, 2012, our restructuring activities primarily consisted of reorganizations within our research and development, manufacturing and software operations. Employee-related costs primarily consist of employee severance and benefits. Facility-related costs primarily consist of charges associated with closing facilities, related lease obligations, and other related costs.

For the three and nine months ended December 29, 2012, we incurred $2.9 million and $5.2 million of restructuring charges. Restructuring expenses have been primarily included as a component of selling, general and administrative expense in the accompanying statements of income. We anticipate that we will incur additional restructuring charges related to these initiatives over the remaining three months of fiscal 2013.

The following summarizes the restructuring activity for the nine months ended December 29, 2012 and December 31, 2011, respectively:



	Nine Months Ended December 29, 2012
(in thousands)	Balance at March 31, 2012		Cost Incurred		Payments			Restructuring Accrual Balance at December 29, 2012
Employee-related costs	$	1,461	$	4,807	$	(3,682	)	$	2,586
Facility-related costs	533		418		(741		)	210
	$	1,994	$	5,225	$	(4,423	)	$	2,796



	Nine Months Ended December 31, 2011
(in thousands)	Balance at April 2, 2011		Cost Incurred		Payments			Restructuring Accrual Balance at December 31, 2011
Employee-related costs	$	2,782	$	3,732	$	(3,899	)	$	2,615
Facility-related costs	889		1,127		(1,269		)	747
	$	3,671	$	4,859	$	(5,168	)	$	3,362

- Definition

The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.

+ References + Details

CAPITALIZATION OF SOFTWARE DEVELOPMENT COSTS	9 Months Ended
CAPITALIZATION OF SOFTWARE DEVELOPMENT COSTS	Dec. 29, 2012
Capitalization of Software and Development Costs [Abstract]
CAPITALIZATION OF SOFTWARE DEVELOPMENT COSTS	CAPITALIZATION OF SOFTWARE DEVELOPMENT COSTS For costs incurred related to the development of software to be sold, leased, or otherwise marketed, we apply the provisions of ASC Topic 985-20, Software - Costs of Software to be Sold, Leased or Marketed, which specifies that costs incurred internally in researching and developing a computer software product should be charged to expense until technological feasibility has been established for the product. Once technological feasibility is established, all software costs should be capitalized until the product is available for general release to customers. We capitalized $4.7 million and $4.4 million in software development costs for ongoing initiatives during the nine month periods ended December 29, 2012 and December 31, 2011, respectively. At December 29, 2012 and March 31, 2012, we have a total of $18.4 million and $15.4 million, respectively, of costs capitalized related to in-process software development initiatives. During the first quarter of fiscal 2013, $1.7 million of capitalized costs related to one project were placed into service. The costs capitalized for each project are included in intangible assets in the consolidated financial statements.

- Definition

The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23218-108380

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 86
-Paragraph 11, 12
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 2
-Paragraph 12, 13
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Audit and Accounting Guide (AAG)
-Number AAG-FGC
-Paragraph 56, 57
-IssueDate 2006-05-01
-Chapter 3
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 68
-Paragraph 14
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

DEBT

9 Months Ended

Dec. 29, 2012

Debt Disclosure [Abstract]

DEBT

Our debt as of December 29, 2012 and March 31, 2012 consists of the following:



(in thousands)	December 29, 2012			March 31, 2012
Term loan	$	475,000		$	—
Mortgage	3,107			3,771
Bank loan	4,340			—
Less current portion	(14,197		)	(894		)
Long term debt less current portion	$	468,250		$	2,877

On August 1, 2012 in connection with the acquisition of the whole blood business, we entered into a credit agreement ("Credit Agreement") with the banks listed below (together, “Lenders”) which provided for a $475.0 million term loan and a $50.0 million revolving loan (the “Revolving Credit Facility,” and together with the Term Loan, (the “Credit Facilities”). The Credit Facilities have a term of five years and mature on August 1, 2017.

Under the terms of this Credit Agreement, the Company may borrow at a spread to an index, including the LIBOR index of 1-month, 3-months, 6-months, etc. From the date of the Credit Agreement, the Company has chosen to borrow against the 1-month USD-LIBOR-BBA rounded up, if necessary, to the nearest 1/16^th of 1% (“Adjusted LIBOR”). The terms of the Credit Agreement also allow the Company to borrow in multiple tranches. While the Company currently borrows in a single tranche, in the future, it may choose to borrow in multiple tranches.

At closing, we borrowed the Term Loan and used the proceeds to pay Pall for the acquisition of the assets described in Note 3. The $475.0 million Term Loan bears interest at variable rates determined by Adjusted LIBOR plus a range of 1.125% to 1.500% depending on the achievement of certain leverage ratios. The Revolving Credit Facility bears interest at variable rates similar to the Term Loan. The current margin of the Term Loan is 1.375% over Adjusted LIBOR and our effective interest rate inclusive of prepaid financing costs and other fees was 2.0%.

Revolving loans may be borrowed, repaid and re-borrowed to fund our working capital needs and for other general corporate purposes. No amounts were outstanding under the Revolving Credit Facility at December 29, 2012. The Term Loan or portions thereof may be prepaid at any time, or from time to time without penalty. Once repaid, such amount may not be re-borrowed. The principal amount of the term loan is repayable quarterly over five years and amortizes as follows:


•	0% during the first year


•	7.5% during the second year


•	12.5% during the third year


•	17.5% during the fourth year and


•	62.5% during the fifth year.

Under the Credit Facilities, we are required to maintain a Consolidated Total Leverage Ratio not to exceed 3.0:1.0 and a Consolidated Interest Coverage Ratio not to be less than 4.0:1.0 during periods when the Credit Facilities are outstanding. In addition, we are required to satisfy these covenants, on a pro forma basis, in connection with any new borrowings (including any letter of credit issuances) on the Revolving Credit Facility as of the time of such borrowings. The Consolidated Interest Coverage Ratio is calculated as the Consolidated EBITDA divided by Consolidated Interest Expense while the Consolidated Total Leverage Ratio is calculated as Consolidated Total Debt divided by Consolidated EBITDA. Consolidated EBITDA includes EBITDA adjusted by non-recurring and unusual transactions specifically as defined in the Credit Facilities.

The Credit Facilities also contain usual and customary non-financial affirmative and negative covenants which include certain restrictions with respect to subsequent indebtedness, liens, loans and investments (including acquisitions), financial reporting obligations, mergers, consolidations, dissolutions or liquidation, asset sales, affiliate transactions, change of our business, capital expenditures, share repurchase and other restricted payments. These covenants are subject to important exceptions and qualifications set forth in the Credit Agreement.

Any failure to comply with the financial and operating covenants of the Credit Facilities would prevent us from being able to borrow additional funds and would constitute a default, which could result in, among other things, the amounts outstanding including all accrued interest and unpaid fees, becoming immediately due and payable. In addition, the Credit Facilities include customary events of default, in certain cases subject to customary cure periods. As of December 29, 2012, we were in compliance with the covenants.

Commitment fee

Pursuant to the Credit Agreement we are required to pay the Lenders, on the last day of each calendar quarter, a commitment fee on the unused portion of the Revolving Credit Facility. The commitment fee is subject to a pricing grid based on our Consolidated Total Leverage Ratio. The commitment fee ranges from 0.175% to 0.300%. The current commitment fee on the undrawn portion of the Revolving Credit Facility is 0.250%.

We may elect to increase the size of the Revolving Credit Facility from $50.0 million to $100.0 million. Alternatively, we may elect to enter into additional term loans up to a $100.0 million combined limit with the Revolving Credit Facility. These elections are subject to the approval of the Administrative Agent and the identification of additional Lenders or current Lenders willing to increase their loan amounts per the terms and conditions contained in the Credit Agreement.

Debt issuance costs and interest

Expenses associated with the issuance of the Term Loan were capitalized and are amortized over the five years using the effective interest method. In connection with the Term Loans, we recorded deferred financing costs of $5.5 million.

Interest expense was $2.3 million and $4.0 million for the three and nine months ended December 29, 2012, respectively. Accrued interest associated with our outstanding debt is included as a component of accrued expenses and other current liabilities in the accompanying condensed consolidated balance sheets. As of December 29, 2012, accrued interest totaled $0.7 million.

Parties to the credit facilities

The Lenders party to the Credit Agreement are JP Morgan Chase Bank, N.A., as Administrative Agent, Citibank, N.A. as Syndication Agent, J P Morgan Securities LLC and Citibank, N.A. as Joint Lead Arrangers and Joint Bookrunners, Bank of America, N.A., RBS Citizens, N.A., HSBC Bank USA, N.A., Wells Fargo Bank, N.A., Sumitomo Mitsui Banking Corporation, TD Bank, N.A. and US Bank, N.A. as Co-Documentation Agents, Union Bank, N.A., PNC Bank, National Association and Sovereign Bank, N.A. as Senior Managing Agents and the syndicate lenders that are parties thereto.

The other debt as of December 29, 2012 includes the real estate mortgage loan of $3.1 million described in our annual financial statements and short term bank borrowings of $4.3 million.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References + Details

ACQUISITIONS (Tables)

9 Months Ended

Dec. 29, 2012

Business Combinations [Abstract]

Schedule of Purchase Price Allocation



Asset class	Amounts Recognized as of December 29, 2012 (Provisional)
(in thousands)
Inventories	$	50,741
Property, plant and equipment	93,847
Intangible assets	188,500
Other assets/liabilities, net	320
Goodwill	206,303
Fair value of net assets acquired	$	539,711

Business Acquisition, Pro Forma Information



	Nine Months Ended
(in thousands)	December 29, 2012		December 31, 2011
Net sales	$	713,981	$	703,023
Net income	42,975		47,961
Basic earnings per share	$	0.84	$	0.94
Diluted earnings per share	$	0.82	$	0.93



	Nine Months Ended
(in thousands)	December 29, 2012			December 31, 2011
Transaction costs (1)	$	3,184		$	—
Amortization of inventory fair value adjustment (2)	11,067			(11,067		)
Amortization of acquired intangible assets (3)	(5,712		)	(12,852		)
Interest expense incurred on acquisition financing (4)	(3,173		)	(7,137		)
Selling, general and admin expenses (5)	(3,513		)	(7,905		)

- Definition

Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.

+ References + Details

EARNINGS PER SHARE ("EPS") (Tables)

9 Months Ended

Dec. 29, 2012

Earnings Per Share [Abstract]

Schedule of Earnings Per Share Reconciliation



	Three Months Ended
	December 29, 2012		December 31, 2011
	(in thousands, except per share amounts)
Basic EPS
Net income	$	9,904	$	18,252
Weighted average shares	51,707		50,154
Basic income per share	$	0.19	$	0.36
Diluted EPS
Net income	$	9,904	$	18,252
Basic weighted average shares	51,707		50,154
Net effect of common stock equivalents	899		722
Diluted weighted average shares	52,606		50,876
Diluted income per share	$	0.19	$	0.36



	Nine Months Ended
	December 29, 2012		December 31, 2011
	(in thousands, except per share amounts)
Basic EPS
Net income	$	26,239	$	49,080
Weighted average shares	51,364		50,818
Basic income per share	$	0.51	$	0.97
Diluted EPS
Net income	$	26,239	$	49,080
Basic weighted average shares	51,364		50,818
Net effect of common stock equivalents	900		848
Diluted weighted average shares	52,264		51,666
Diluted income per share	$	0.50	$	0.95

STOCK-BASED COMPENSATION (Tables)

9 Months Ended

Dec. 29, 2012

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Assumptions Utilized for Estimating Fair Value of Option Grants

The assumptions utilized for estimating the fair value of option grants during the periods presented are as follows:



	Nine Months Ended
	December 29, 2012		December 31, 2011
Stock Options Black-Scholes assumptions (weighted average):
Volatility	26.94	%	27.95	%
Expected life (years)	5.0		4.9
Risk-free interest rate	0.72	%	1.12	%
Dividend yield	—	%	—	%

PRODUCT WARRANTIES (Tables)

9 Months Ended

Dec. 29, 2012

Product Warranties [Abstract]

Schedule of Product Warranty Liability

We estimate our potential warranty expense based on our historical warranty experience, and we periodically assess the adequacy of our warranty accrual and make adjustments as necessary.



	Nine Months Ended
(in thousands)	December 29, 2012			December 31, 2011
Warranty accrual as of the beginning of the period	$	796		$	1,273
Warranty provision	884			1,897
Warranty spending	(1,076		)	(1,680		)
Warranty accrual as of the end of the period	$	604		$	1,490

INVENTORIES (Tables)

9 Months Ended

Dec. 29, 2012

Inventory Disclosure [Abstract]

Schedule of Inventories

Inventories are stated at the lower of cost or market and include the cost of material, labor and manufacturing overhead. Cost is determined on the first-in, first-out method.



(in thousands)	December 29, 2012		March 31, 2012
Raw materials	$	58,508	$	41,219
Work-in-process	8,979		4,640
Finished goods	112,550		71,304
	$	180,037	$	117,163

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Tables)

9 Months Ended

Dec. 29, 2012

Derivatives and Fair Value Measurements [Abstract]

Schedule of Effect of Derivative Instruments Designated as Cash Flow Hedges and Those Not Designated as Hedging Instruments



Derivative Instruments	Amount of Loss Recognized in AOCI (Effective Portion)			Amount of Loss Reclassified from AOCI into Earnings (Effective Portion)		Location in Statement of Operations	Amount of loss Excluded from Effectiveness Testing (*)			Location in Statement of Operations
(in thousands)
Designated foreign currency hedge contracts, net of tax	$	(374	)	$	2,011	Net revenues, COGS, and SG&A	$	(380	)	Other income (expense), net
Non-designated foreign currency hedge contracts	—			—			(930		)	Other income (expense)
Designated interest rate swaps, net of tax	576			$	—	Interest income (expense), net	$	—

(*) We exclude the difference between the spot rate and hedge forward rate from our effectiveness testing.

Schedule of Fair Value of Derivative Instruments as They Appear in Consolidated Balance Sheets



(in thousands)	Location in Balance Sheet	As of December 29, 2012		As of March 31, 2012
Derivative Assets:
Designated foreign currency hedge contracts	Other current assets	$	3,904	$	6,186
		$	3,904	$	6,186
Derivative Liabilities:
Designated foreign currency hedge contracts	Other current liabilities	$	1,343	$	1,185
Designated interest rate swaps	Other current liabilities	$	927	$	—
		$	2,270	$	1,185

Schedule of Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis

Financial assets and financial liabilities measured at fair value on a recurring basis consist of the following as of December 29, 2012:



(in thousands)	Quoted Market Prices for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
Assets
Money market funds	$	142,919	$	—	$	—	$	142,919
Foreign currency hedge contracts	—		$	3,904	—		3,904
	$	142,919	$	3,904	$	—	$	146,823
Liabilities
Foreign currency hedge contracts	$	—	$	1,343	$	—	$	1,343
Interest rate swap	—		927		—		927
	$	—	$	2,270	$	—	$	2,270

- Definition

Tabular disclosure of the location and amount of gains and losses reported in the statement of financial performance, or when applicable, the statement of financial position. For example, (a) gains and losses recognized in the income statement on derivative instruments designated and qualifying as hedging instruments in fair value hedges and related hedged items designated and qualifying in fair value hedges and (b) gains and losses initially recognized in other comprehensive income on derivative instruments designated and qualifying as cash flow hedges.

+ References + Details

SEGMENT INFORMATION (Tables)

9 Months Ended

Dec. 29, 2012

Segment Reporting [Abstract]

Schedule of Revenues from External Customers

evenues from External Customers:



	Three Months Ended
(in thousands)	December 29, 2012		December 31, 2011
Disposable revenues
Plasma disposables	$	68,102	$	69,040
Blood center disposables
Platelet	45,139		44,383
Red cell	11,752		12,162
Whole blood	54,894		—
	111,785		56,545
Hospital disposables
Surgical	18,900		17,333
OrthoPAT	7,090		7,755
Diagnostics	6,761		5,681
	32,751		30,769
Disposables revenue	212,638		156,354
Software solutions	16,008		15,849
Equipment & other	18,749		18,957
Net revenues	$	247,395	$	191,160



	Nine Months Ended
(in thousands)	December 29, 2012		December 31, 2011
Disposable revenues
Plasma disposables	$	200,657	$	196,206
Blood center disposables
Platelet	125,579		123,888
Red cell	35,738		35,676
Whole blood	83,514		—
	244,831		159,564
Hospital disposables
Surgical	55,965		49,281
OrthoPAT	22,276		22,804
Diagnostics	20,196		16,955
	98,437		89,040
Disposables revenue	543,925		444,810
Software solutions	51,354		51,208
Equipment & other	46,769		45,156
Net revenues	$	642,048	$	541,174

RESTRUCTURING (Tables)

9 Months Ended

Dec. 29, 2012

Restructuring and Related Activities [Abstract]

Schedule of Restructuring Reserve by Type of Cost

The following summarizes the restructuring activity for the nine months ended December 29, 2012 and December 31, 2011, respectively:



	Nine Months Ended December 29, 2012
(in thousands)	Balance at March 31, 2012		Cost Incurred		Payments			Restructuring Accrual Balance at December 29, 2012
Employee-related costs	$	1,461	$	4,807	$	(3,682	)	$	2,586
Facility-related costs	533		418		(741		)	210
	$	1,994	$	5,225	$	(4,423	)	$	2,796



	Nine Months Ended December 31, 2011
(in thousands)	Balance at April 2, 2011		Cost Incurred		Payments			Restructuring Accrual Balance at December 31, 2011
Employee-related costs	$	2,782	$	3,732	$	(3,899	)	$	2,615
Facility-related costs	889		1,127		(1,269		)	747
	$	3,671	$	4,859	$	(5,168	)	$	3,362

DEBT (Tables)

9 Months Ended

Dec. 29, 2012

Debt Disclosure [Abstract]

Schedule of Long-term Debt

Our debt as of December 29, 2012 and March 31, 2012 consists of the following:



(in thousands)	December 29, 2012			March 31, 2012
Term loan	$	475,000		$	—
Mortgage	3,107			3,771
Bank loan	4,340			—
Less current portion	(14,197		)	(894		)
Long term debt less current portion	$	468,250		$	2,877

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6584090&loc=d3e28878-108400

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28541-108399

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 22
-Article 5

+ Details

BASIS OF PRESENTATION (Narrative) (Details)	3 Months Ended	9 Months Ended	12 Months Ended
BASIS OF PRESENTATION (Narrative) (Details)	Dec. 29, 2012	Dec. 29, 2012	Mar. 31, 2012
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Term of each fiscal quarter		1 year	1 year
Term of each quarter		3 months	3 months
Stock split, conversion ratio	2

ACQUISITIONS (Details) - USD ($)
$ / shares in Units, $ in Thousands

3 Months Ended

9 Months Ended

Dec. 29, 2012

Dec. 31, 2011

Dec. 29, 2012

Dec. 31, 2011

Aug. 01, 2012

Asset class

Cost of goods sold

$ 134,280

$ 95,229

$ 337,058

$ 266,545

Pall Corporation [Member]

Business Acquisition [Line Items]

Business acquistion, cost of aquired entity

$ 535,100

Business acqusition, post closing adjustmetns accrued

4,600

Business acquisition, additional anticipated payment

15,000

Face amount of debt

475,000

Asset class

Inventories

50,741

Property, plant and equipment

93,847

Intangible assets

188,500

Other assets/liabilities, net

320

Goodwill

206,303

Fair value of net assets acquired

539,711

Revenue since acquisition

83,500

Earnings since acquisition

8,000

Cost of goods sold

11,100

Business Acquisition, Pro Forma Information [Abstract]

Net sales

713,981

703,023

Net income

$ 42,975

$ 47,961

Basic earnigs per share (in dollars per share)

$ 0.84

$ 0.94

Diluted earnigs per share (in dollars per share)

$ 0.82

$ 0.93

Transaction costs

^[1]

3,184

$ 3,184

$ 0

Amortization of inventory fair value adjustment

^[2]

11,067

(11,067)

11,067

(11,067)

Amortization of acquired intangible assets

^[3]

(5,712)

(12,852)

(5,712)

(12,852)

Interest expense incurred on acquisition financing

^[4]

(3,173)

(7,137)

(3,173)

(7,137)

Selling, general and admin expenses

^[5]

(3,513)

$ (7,905)

(3,513)

$ (7,905)

Amount of transaction prior to acquisition

$ 10,000

Acquired Technology [Member] | Pall Corporation [Member]

Asset class

Intangible assets

61,000

Customer Relationships [Member] | Pall Corporation [Member]

Asset class

Intangible assets

$ 127,500

127,500

Acquired Technology and Customer Relationships [Member] | Pall Corporation [Member]

Asset class

Estimated useful life

11 years

Amortization expense

$ 3,700

7,100

Purchase Price Allocation Adjustments [Member] | Pall Corporation [Member]

Business Acquisition [Line Items]

Business acquistion, cost of aquired entity

4,500

Asset class

Inventories

(1,700)

Property, plant and equipment

23,100

(18,300)

100

(2,000)

$ (700)

[1]	Eliminated transactions costs as these non-recurring costs were incurred in the first and second quarters of FY13.
[2]	Added additional expense in the period ended December 31, 2011 to reflect the inventory fair value adjustments which would have been amortized had the transaction been consummated on April 3, 2011 as the corresponding inventory would have been completely sold during the first two quarters of 2011. Also, deducted the actual inventory fair value adjustment recorded in the nine months ended December 29, 2012 to reflect the pro-forma consumption of inventory in 2011.
[3]	Added additional amortization of the acquired whole blood intangible assets recognized at fair value in purchase accounting
[4]	Added additional interest expense for the debt used to finance the acquisition.
[5]	Additional investments in infrastructure costs to replicate certain support functions performed by division or corporate organizations of Pall that did not transfer in the acquisition. These costs are primarily related to information technology infrastructure and application costs, and personnel costs required to expand regional and corporate administrative and sales support functions. These costs are not intended to be representative of actual costs incurred by Pall Corporation, and represent Haemonetics' best estimate of future incremental costs on an annualized basis. Actual incremental investments may differ from these estimates

EARNINGS PER SHARE ("EPS") (Schedule of Earnings Per Share Reconciliation) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 29, 2012	Dec. 31, 2011	Dec. 29, 2012	Dec. 31, 2011
Basic EPS
Net income	$ 9,904	$ 18,252	$ 26,239	$ 49,080
Basic weighted average shares (in shares)	51,707	50,154	51,364	50,818
Basic income per share (in dollars per share)	$ 0.19	$ 0.36	$ 0.51	$ 0.97
Diluted EPS
Net income	$ 9,904	$ 18,252	$ 26,239	$ 49,080
Basic weighted average shares (in shares)	51,707	50,154	51,364	50,818
Net effect of common stock equivalents (in shares)	899	722	900	848
Diluted weighted average shares (in shares)	52,606	50,876	52,264	51,666
Diluted income per share (in dollars per share)	$ 0.19	$ 0.36	$ 0.50	$ 0.95
Stock options excluded from computation of weighted average shares outstanding (in shares)	700	1,800	400	1,200

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Antidilution
-URI http://asc.fasb.org/extlink&oid=6505113

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Diluted Earnings Per Share
-URI http://asc.fasb.org/extlink&oid=6510752

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Contingent Stock Agreement
-URI http://asc.fasb.org/extlink&oid=6508534

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 40
-Subparagraph c
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 13, 14
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 07-4
-Paragraph 4
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 171
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.21)
-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=16381557&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.23)
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 18
-Article 7

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 36, 37, 38
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 07-4
-Paragraph 4
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 20
-Article 5

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 21
-Article 9

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=6518256

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.18)
-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.22)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=6519514

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e565-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 10, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph A7
-Appendix A

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 87-21
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 19
-Article 5

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28, 29, 30
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 20
-Article 9

+ Details

- Definition

The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.

+ References + Details

- Definition

Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Weighted-Average Number of Common Shares Outstanding
-URI http://asc.fasb.org/extlink&oid=6528421

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 07-4
-Paragraph 4
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 8
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 171
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 40
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

STOCK-BASED COMPENSATION (Assumptions Utilized for Estimating Fair Value of Option Grants) (Details)	9 Months Ended
	Dec. 29, 2012	Dec. 31, 2011
Stock Options Black-Scholes assumptions (weighted average):
Volatility	26.94%	27.95%
Expected life (years)	4 years 11 months 19 days	4 years 10 months 24 days
Risk-free interest rate	0.72%	1.12%
Dividend yield	0.00%	0.00%

STOCK-BASED COMPENSATION (Narrative) (Details) - USD ($) $ / shares in Units, $ in Millions	9 Months Ended
	Dec. 29, 2012	Dec. 31, 2011
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-based compensation expense recognized	$ 7.9	$ 6.7
Income tax benefit recognized related to stock-based compensation	$ 2.5	$ 2.0
Weighted average fair value of options granted	$ 9.76	$ 8.15
Shares purchased under the ESPP	150,763	154,520
Shares purchased under the ESPP, value per share	$ 27.47	$ 24.58

- Definition

Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.

+ References + Details

- Definition

Number of shares issued during the period as a result of an employee stock purchase plan.

+ References + Details

PRODUCT WARRANTIES (Schedule of Product Warranty Liability) (Details) - USD ($) $ in Thousands	9 Months Ended
	Dec. 29, 2012	Dec. 31, 2011
Product Warranties [Roll Forward]
Warranty accrual as of the beginning of the period	$ 796	$ 1,273
Warranty provision	884	1,897
Warranty spending	(1,076)	(1,680)
Warranty accrual as of the end of the period	$ 604	$ 1,490

COMPREHENSIVE INCOME (Schedule of Comprehensive Income (Loss)) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 29, 2012	Dec. 31, 2011	Dec. 29, 2012	Dec. 31, 2011
Comprehensive Income [Abstract]
Net income	$ 9,904	$ 18,252	$ 26,239	$ 49,080
Other comprehensive income:
Total comprehensive income	$ 12,239	$ 18,585	$ 24,020	$ 48,657

- Definition

The change in equity [net assets] of a business enterprise during a period from transactions and other events and circumstances from non-owner sources which are attributable to the reporting entity. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners, but excludes any and all transactions which are directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent.

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

INVENTORIES (Schedule of Inventories) (Details) - USD ($) $ in Thousands	Dec. 29, 2012	Mar. 31, 2012
Inventory Disclosure [Abstract]
Raw materials	$ 58,508	$ 41,219
Work-in-process	8,979	4,640
Finished goods	112,550	71,304
Inventories, net	$ 180,037	$ 117,163

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Schedule of Effect of Derivative Instruments Designated as Cash Flow Hedges and Those Not Designated as Hedging Instruments) (Details)
$ in Thousands

9 Months Ended

Dec. 29, 2012

USD ($)

Designated as Hedging Instrument | Cash Flow Hedging | Foreign Exchange Contract

Derivative Instruments, Gain (Loss) [Line Items]

Amount of Loss Recognized in AOCI (Effective Portion)

$ (374)

Designated as Hedging Instrument | Cash Flow Hedging | Foreign Exchange Contract | Net revenues, COGS, and SG&A

Derivative Instruments, Gain (Loss) [Line Items]

Amount of Loss Reclassifiedfrom AOCI into Earnings (Effective Portion)

2,011

Designated as Hedging Instrument | Cash Flow Hedging | Foreign Exchange Contract | Other Income (Expense), Net [Member]

Derivative Instruments, Gain (Loss) [Line Items]

Amount Excluded from Effectiveness Testing

(380)

^[1]

Designated as Hedging Instrument | Interest Rate Swap [Member]

Derivative Instruments, Gain (Loss) [Line Items]

Amount of Loss Recognized in AOCI (Effective Portion)

(576)

Amount Excluded from Effectiveness Testing

Designated as Hedging Instrument | Interest Rate Swap [Member] | Interest Income (Expense), Net [Member]

Derivative Instruments, Gain (Loss) [Line Items]

Amount of Loss Reclassifiedfrom AOCI into Earnings (Effective Portion)

Not Designated as Hedging Instrument | Foreign Exchange Contract

Derivative Instruments, Gain (Loss) [Line Items]

Amount of Loss Recognized in AOCI (Effective Portion)

Amount of Loss Reclassifiedfrom AOCI into Earnings (Effective Portion)

Not Designated as Hedging Instrument | Foreign Exchange Contract | Other Income (Expense), Net [Member]

Derivative Instruments, Gain (Loss) [Line Items]

Amount Excluded from Effectiveness Testing

$ (930)

^[1]

[1]	We exclude the difference between the spot rate and hedge forward rate from our effectiveness testing.

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Schedule of Fair Value of Derivative Instruments as They Appear in Consolidated Balance Sheets) (Details) - USD ($) $ in Thousands	Dec. 29, 2012	Mar. 31, 2012
Derivative Assets:
Derivative Assets	$ 3,904	$ 6,186
Derivative Liabilities:
Derivative Liabilities	2,270	1,185,000
Cash Flow Hedging \| Foreign Exchange Contract \| Other Current Assets
Derivative Assets:
Derivative Assets	3,904	6,186
Cash Flow Hedging \| Foreign Exchange Contract \| Other Current Liabilities
Derivative Liabilities:
Derivative Liabilities	1,343	1,185,000
Interest Rate Swap [Member] \| Other Current Liabilities
Derivative Liabilities:
Derivative Liabilities	$ 927	$ 0

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Schedule of Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis) (Details) - USD ($) $ in Thousands	Dec. 29, 2012	Mar. 31, 2012
Assets
Money market funds	$ 142,919
Foreign currency hedge contracts	3,904
Derivative Assets	3,904	$ 6,186
Assets, Fair Value Disclosure, Total	146,823
Liabilities
Foreign currency hedge contracts	1,343
Derivative Liabilities	2,270	1,185,000
Derivative Financial Instruments, Liabilities, Fair Value Disclosure	927
Liabilities, Fair Value Disclosure	2,270
Fair Value, Inputs, Level 1
Assets
Money market funds	142,919
Foreign currency hedge contracts	0
Assets, Fair Value Disclosure, Total	142,919
Liabilities
Foreign currency hedge contracts	0
Derivative Financial Instruments, Liabilities, Fair Value Disclosure	0
Liabilities, Fair Value Disclosure	0
Fair Value, Inputs, Level 2
Assets
Money market funds	0
Derivative Assets	3,904
Assets, Fair Value Disclosure, Total	3,904
Liabilities
Derivative Liabilities	1,343
Derivative Financial Instruments, Liabilities, Fair Value Disclosure	927
Liabilities, Fair Value Disclosure	2,270
Fair Value, Inputs, Level 3
Assets
Money market funds	0
Foreign currency hedge contracts	0
Assets, Fair Value Disclosure, Total	0
Liabilities
Foreign currency hedge contracts	0
Derivative Financial Instruments, Liabilities, Fair Value Disclosure	0
Liabilities, Fair Value Disclosure	0
Cash Flow Hedging \| Other Current Assets \| Foreign Exchange Contract
Assets
Derivative Assets	3,904	6,186
Cash Flow Hedging \| Other Current Liabilities \| Foreign Exchange Contract
Liabilities
Derivative Liabilities	1,343	1,185,000
Interest Rate Swap [Member] \| Other Current Liabilities
Liabilities
Derivative Liabilities	$ 927	$ 0

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Narrative) (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended
	Sep. 30, 2011	Dec. 29, 2012	Dec. 31, 2011	Dec. 29, 2012	Dec. 31, 2011	Aug. 01, 2012	Mar. 31, 2012
Derivative [Line Items]
Maturity period for foreign currency contracts (in years)		1 year
Designated foreign currency hedge contracts outstanding		$ 133,400		$ 133,400			$ 162,100
Non-designated foreign currency hedge contracts outstanding		68,900		68,900			45,500
Contingent consideration income		0	$ 0	0	$ (1,580)
Contingent consideration payment recorded in selling, general and administrative	$ 700
Fair value of real estate mortgage obligation		$ 2,270		$ 2,270
Debt Instrument, Description of Variable Rate Basis				LIBOR
Designated as Hedging Instrument \| Cash Flow Hedging \| Foreign Exchange Contract
Derivative [Line Items]
Cash Flow Hedge Gain Reclassified to Earnings				$ 2,011
Recognized net losses in earnings on cash flow hedges					$ (400)
Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net				374
Designated as Hedging Instrument \| Interest Rate Swap [Member]
Derivative [Line Items]
Cash Flow Hedge Gain (Loss) to be Reclassified within Twelve Months				$ 94
Derivative, Fixed Interest Rate		0.68%		0.68%
Derivative, Notional Amount		$ 250,000		$ 250,000
Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net				$ 576
Foreign Country
Derivative [Line Items]
Percentage of sales generated outside the US				49.40%
Mortgage Loans on Real Estate
Derivative [Line Items]
Fair value of real estate mortgage obligation		$ 2,300		$ 2,300			$ 3,100
Credit Agreement [Member]
Derivative [Line Items]
Debt Instrument, Description of Variable Rate Basis				1-month USD-LIBOR-BBA
Adjusted Libor Rounding Percentage		0.625%		0.625%
Pall Corporation [Member]
Derivative [Line Items]
Face amount of debt						$ 475,000

INCOME TAXES (Details)	3 Months Ended	9 Months Ended
INCOME TAXES (Details)	Dec. 29, 2012	Dec. 29, 2012
Income Tax Disclosure [Abstract]
Reported tax rate	25.00%	25.50%

COMMITMENTS AND CONTINGENCIES (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 29, 2012	Dec. 31, 2011	Dec. 29, 2012	Dec. 31, 2011
Loss Contingencies [Line Items]
Inventory reserves recorded in cost of good sold	$ 134,280	$ 95,229	$ 337,058	$ 266,545
Certain Whole Blood Collection Sets [Member]
Loss Contingencies [Line Items]
Inventory reserves recorded in cost of good sold	6,100
High Separation Core Bowl [Member]
Loss Contingencies [Line Items]
Accrued loss contingency liability	10,300		10,300
Insurance settlements receivable	$ 8,200		8,200
Recorded expense, net of insurance recovery			$ 2,100

SEGMENT INFORMATION (Revenues from External Customers) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 29, 2012	Dec. 31, 2011	Dec. 29, 2012	Dec. 31, 2011
Revenue from External Customer [Line Items]
Net revenues	$ 247,395	$ 191,160	$ 642,048	$ 541,174
Reportable Segment [Member]
Revenue from External Customer [Line Items]
Net revenues	212,638	156,354	543,925	444,810
Reportable Segment [Member] \| Plasma Disposables [Member]
Revenue from External Customer [Line Items]
Net revenues	68,102	69,040	200,657	196,206
Reportable Segment [Member] \| Blood Center [Member]
Revenue from External Customer [Line Items]
Net revenues	111,785	56,545	244,831	159,564
Reportable Segment [Member] \| Platelet [Member]
Revenue from External Customer [Line Items]
Net revenues	45,139	44,383	125,579	123,888
Reportable Segment [Member] \| Red Cell [Member]
Revenue from External Customer [Line Items]
Net revenues	11,752	12,162	35,738	35,676
Reportable Segment [Member] \| Whole Blood [Member]
Revenue from External Customer [Line Items]
Net revenues	54,894	0	83,514	0
Reportable Segment [Member] \| Hospital [Member]
Revenue from External Customer [Line Items]
Net revenues	32,751	30,769	98,437	89,040
Reportable Segment [Member] \| Surgical [Member]
Revenue from External Customer [Line Items]
Net revenues	18,900	17,333	55,965	49,281
Reportable Segment [Member] \| OrthoPAT [Member]
Revenue from External Customer [Line Items]
Net revenues	7,090	7,755	22,276	22,804
Reportable Segment [Member] \| Diagnostics [Member]
Revenue from External Customer [Line Items]
Net revenues	6,761	5,681	20,196	16,955
Reportable Segment [Member] \| Software Solutions [Member]
Revenue from External Customer [Line Items]
Net revenues	16,008	15,849	51,354	51,208
Reportable Segment [Member] \| Equipment and Other [Member]
Revenue from External Customer [Line Items]
Net revenues	$ 18,749	$ 18,957	$ 46,769	$ 45,156

RESTRUCTURING (Schedule of Restructuring Reserve by Type of Cost) (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Dec. 29, 2012	Dec. 29, 2012	Dec. 31, 2011
Restructuring Reserve [Roll Forward]
Beginning Balance		$ 1,994	$ 3,671
Cost Incurred	$ 2,900	5,225	4,859
Payments		(4,423)	(5,168)
Ending Balance	2,796	2,796	3,362
Employee-related costs
Restructuring Reserve [Roll Forward]
Beginning Balance		1,461	2,782
Cost Incurred		4,807	3,732
Payments		(3,682)	(3,899)
Ending Balance	2,586	2,586	2,615
Facility-related costs
Restructuring Reserve [Roll Forward]
Beginning Balance		533	889
Cost Incurred		418	1,127
Payments		(741)	(1,269)
Ending Balance	$ 210	$ 210	$ 747

RESTRUCTURING (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Dec. 29, 2012	Dec. 29, 2012	Dec. 31, 2011
Restructuring Cost and Reserve [Line Items]
Restructuring charges incurred	$ 2,900	$ 5,225	$ 4,859

CAPITALIZATION OF SOFTWARE DEVELOPMENT COSTS (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Jul. 02, 2011	Dec. 29, 2012	Dec. 31, 2011
Capitalization of Software and Development Costs [Abstract]
Capitalized software development costs for ongoing initiatives	$ 1.7	$ 4.7	$ 4.4
Total costs capitalized related to in process software development initiatives		$ 18.4	$ 15.4

- Definition

Research and development expense during the period related to the costs of developing and achieving technological feasibility of a computer software product to be sold, leased, or otherwise marketed.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preliminary Project Stage
-URI http://asc.fasb.org/extlink&oid=6521637

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Research and Development
-URI http://asc.fasb.org/extlink&oid=6523717

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Statement of Position (SOP)
-Number 98-1
-Paragraph 18-26
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 86
-Paragraph 3, 12
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 2
-Paragraph 8, 13
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 00-2
-Section Exhibit 00-2A
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 86
-Paragraph 11
-Subparagraph b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

DEBT (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
DEBT (Details) - USD ($) $ in Thousands	Dec. 29, 2012	Dec. 29, 2012	Aug. 01, 2012	Mar. 31, 2012
Debt Instrument [Line Items]
Less current portion	$ (14,197)	$ (14,197)		$ (894)
Long term debt less current portion	$ 468,250	$ 468,250		2,877
Debt Instrument, Description of Variable Rate Basis		LIBOR
Credit Agreement [Member]
Debt Instrument [Line Items]
Debt Instrument, Description of Variable Rate Basis		1-month USD-LIBOR-BBA
Adjusted Libor Rounding Percentage	0.625%	0.625%
Term Loan [Member]
Debt Instrument [Line Items]
Long-term debt	$ 475,000	$ 475,000		0
Debt Instrument, Interest Rate, Effective Percentage	2.00%	2.00%
Debt Instrument, Amortization Period	5 years	5 years
Deferred Finance Costs, Net	$ 5,500	$ 5,500
Interest Expense, Debt	2,300	4,000
Interest Payable	700	700
Mortgages [Member]
Debt Instrument [Line Items]
Long-term debt	3,107	3,107		3,771
Bank Loan [Member]
Debt Instrument [Line Items]
Long-term debt	$ 4,340	$ 4,340		$ 0
Line of Credit [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate	1.375%	1.375%
Consolidated Total Leverage Ratio	3	3
Consolidated Interest Coverage Ratio	4	4
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage		0.25%
Line of Credit Facility, Expanded Borrowing Capacity Including Term Loans	$ 100,000	$ 100,000
Minimum [Member] \| Term Loan [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate	1.125%	1.125%
Minimum [Member] \| Line of Credit [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage		0.175%
Line of Credit Facility, Expanded Borrowing Capacity	$ 50,000	$ 50,000
Maximum [Member] \| Term Loan [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate	1.50%	1.50%
Maximum [Member] \| Line of Credit [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage		0.30%
Line of Credit Facility, Expanded Borrowing Capacity	$ 100,000	$ 100,000
First Year [Member] \| Line of Credit [Member]
Debt Instrument [Line Items]
Amortization Percentage of Debt	0.00%	0.00%
Second Year [Member] \| Line of Credit [Member]
Debt Instrument [Line Items]
Amortization Percentage of Debt	7.50%	7.50%
Third Year [Member] \| Line of Credit [Member]
Debt Instrument [Line Items]
Amortization Percentage of Debt	12.50%	12.50%
Fourth Year [Member] \| Line of Credit [Member]
Debt Instrument [Line Items]
Amortization Percentage of Debt	17.50%	17.50%
Fifth Year [Member] \| Line of Credit [Member]
Debt Instrument [Line Items]
Amortization Percentage of Debt	62.50%	62.50%
Pall Corporation [Member]
Debt Instrument [Line Items]
Face amount of debt			$ 475,000
Line of Credit Facility, Maximum Borrowing Capacity			$ 50,000
Term of Credit Facilities			5 years